Superior vena cava syndrome screening: Difference between revisions
No edit summary |
Mahshid |
||
Line 20: | Line 20: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Vascular medicine]] | |||
[[Category:Surgery]] |
Revision as of 17:05, 27 November 2017
Superior Vena Cava Syndrome Microchapters |
Differentiating Superior Vena Cava Syndrome from Other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Superior vena cava syndrome screening On the Web |
American Roentgen Ray Society Images of Superior vena cava syndrome screening |
Directions to Hospitals Treating Superior vena cava syndrome |
Risk calculators and risk factors for Superior vena cava syndrome screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
According to the the National Cancer Institute, there is insufficient evidence to recommend routine screening for superior vena cava syndrome.[1]
Screening
According to the the National Cancer Institute, there is insufficient evidence to recommend routine screening for superior vena cava syndrome.[1]
References
- ↑ 1.0 1.1 National Cancer Institute. Cardiopulmonary Syndromes. http://www.cancer.gov/about-cancer/treatment/side-effects/cardiopulmonary-pdq#section/_AboutThis_1 Accessed on January 13, 2016